Related Experiment Video
Updated: May 3, 2026
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Genome-wide profiling identifies the genetic dependencies of cell death following EGFR inhibition
Sydney A Porto1, Gavin A Birdsall1, Nicholas W Harper1
1Department of Systems Biology, UMass Chan Medical School, Worcester, MA USA.
Abstract:
EGFR is a proto-oncogene that is mutationally activated in a variety of cancers. Small molecule inhibitors targeting EGFR can be effective in slowing the progression of disease, and in some settings these drugs even cause dramatic tumor regression. However, responses to EGFR inhibitors are rarely durable, and the mechanisms contributing to response variation remain unclear. In particular, several distinct mechanisms have been proposed for how EGFR inhibition activates cell death, and a consensus has yet to emerge. In this study, we use functional genomics with specialized analyses to infer how genetic perturbations effect the drug-induced death rate. Our data clarify that inhibition of PI3K signaling drives the lethality of EGFR inhibition. Inhibition of other pathways downstream of EGFR, including the RAS-MAPK pathway, promote growth suppression, but not the lethal effects of EGFR inhibitors. Taken together, our study reveals the first "reference map" for the genome-wide genetic dependencies of lethality for EGFR inhibitors.
Insights
Targeting the Epidermal Growth Factor Receptor (EGFR) with inhibitors can treat cancer, but responses are often short-lived. This study reveals that blocking PI3K signaling, not RAS-MAPK, is key to EGFR inhibitor-induced cancer cell death.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The Epidermal Growth Factor Receptor (EGFR) is a proto-oncogene implicated in various cancers.
- Small molecule inhibitors targeting EGFR show promise in cancer treatment, but durable responses are limited.
- Mechanisms underlying EGFR inhibitor efficacy and resistance, particularly regarding cell death induction, require further elucidation.
Purpose of the Study:
- To elucidate the genetic dependencies governing lethality induced by EGFR inhibitors.
- To differentiate pathways mediating growth suppression versus cell death upon EGFR inhibition.
- To establish a genome-wide map of genetic vulnerabilities to EGFR inhibitors.
Main Methods:
- Utilized functional genomics screens to assess the impact of genetic perturbations on drug-induced lethality.
- Applied specialized computational analyses to interpret high-throughput genetic screening data.
- Investigated downstream signaling pathways of EGFR, including PI3K and RAS-MAPK.
Main Results:
- Identified Phosphatidylinositol 3-Kinase (PI3K) signaling inhibition as the primary driver of cell death induced by EGFR inhibitors.
- Demonstrated that inhibition of the RAS-MAPK pathway downstream of EGFR mediates growth suppression but not lethality.
- Generated a comprehensive genome-wide reference map detailing genetic dependencies for EGFR inhibitor-induced lethality.
Conclusions:
- PI3K pathway inhibition is critical for the lethal effects of EGFR inhibitors in cancer.
- RAS-MAPK pathway activity contributes to growth inhibition but not cell death under EGFR inhibition.
- The developed reference map provides crucial insights into the genetic basis of EGFR inhibitor response and resistance.
